We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Northwest Biotherapeutics Inc (QB) | USOTC:NWBO | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0102 | -3.11% | 0.3182 | 0.317 | 0.3465 | 0.3354 | 0.3174 | 0.325 | 1,014,347 | 21:59:00 |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 5 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 11 | | | |
| | | | 12 | | | |
| | | | 14 | | | |
| | | | 16 | | | |
| | | | 18 | | | |
| | | | 21 | | | |
| | | | 28 | | | |
| | | | 29 | | | |
| | | | 30 | | |
Name
|
| |
Age
|
| |
Position
|
|
Linda F. Powers | | |
67
|
| | Class III Director, Chairperson, President and Chief Executive Officer, Chief Financial and Accounting Officer | |
J. Cofer Black | | |
72
|
| | Class I Director | |
Dr. Alton L. Boynton | | |
78
|
| | Class I Director, Chief Scientific Officer | |
Jerry Jasinowski | | |
83
|
| | Class II Director | |
Dr. Navid Malik | | |
53
|
| | Class III Director | |
Name of Beneficial Owner
|
| |
Number of
Shares Beneficially Owned |
| |
Percentage(1)
|
| ||||||
Directors and Officers: | | | | | | | | | | | | | |
Alton L. Boynton, Ph.D.
|
| | | | 21,773,445 | | | | | | 2.0% | | |
Marnix L. Bosch, Ph.D., M.B.A.
|
| | | | 35,379,439 | | | | | | 3.3% | | |
Linda F. Powers(2)
|
| | | | 29,411,759 | | | | | | 2.8% | | |
Leslie J. Goldman(3)
|
| | | | 172,742 | | | | | | *% | | |
Dr. Navid Malik
|
| | | | 9,075,000 | | | | | | *% | | |
Jerry Jasinowski
|
| | | | 8,232,204 | | | | | | *% | | |
J. Cofer Black
|
| | | | 1,715,000 | | | | | | *% | | |
All executive officers and directors as a group (seven persons)
|
| | | | 105,759,589 | | | | | | 9.4% | | |
Name and Principal Position
|
| |
Year
|
| |
Salary
($) |
| |
Bonus
($) |
| |
Option
Awards ($)(2) |
| |
Total
($) |
| |||||||||||||||
Linda F. Powers
Chairperson, President and Chief Executive Officer, Chief Financial and Accounting Officer |
| | | | 2021 | | | | | | 700,000 | | | | | | 300,000(1) | | | | | | — | | | | | | 1,000,000 | | |
| | | 2020 | | | | | | 700,000 | | | | | | — | | | | | | 17,317,000 | | | | | | 18,017,000 | | | ||
| | | 2019 | | | | | | 502,000 | | | | | | 300,000 | | | | | | — | | | | | | 802,000 | | | ||
Leslie Goldman
Senior Vice President,General Counsel and Business Development |
| | | | 2021 | | | | | | 525,000 | | | | | | 200,000(1) | | | | | | — | | | | | | 725,000 | | |
| | | 2020 | | | | | | 525,000 | | | | | | — | | | | | | 10,548,000 | | | | | | 11,073,000 | | | ||
| | | 2019 | | | | | | 375,000 | | | | | | 200,000 | | | | | | — | | | | | | 575,000 | | | ||
Marnix L. Bosch, Ph.D.(3)
Chief Technical Officer |
| | | | 2021 | | | | | | 480,000 | | | | | | 125,000(1) | | | | | | — | | | | | | 605,000 | | |
| | | 2020 | | | | | | 480,000 | | | | | | — | | | | | | 7,494,000 | | | | | | 7,974,000 | | | ||
| | | 2019 | | | | | | 397,000 | | | | | | 100,000 | | | | | | — | | | | | | 497,000 | | |
Name
|
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable(1) |
| |
Number of
Securities Underlying Unexercised Options (#) Unexercisable |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| ||||||||||||
Linda F. Powers
Chairperson, President and Chief Executive Officer, Chief Financial and Accounting Officer |
| | | | 39,200,000(2) | | | | | | — | | | | | | 0.23 | | | | | | 5/28/2028 | | |
| | | 10,770,429(3) | | | | | | — | | | | | | 0.35 | | | | | | 7/2/2030 | | | ||
| | | 32,558,754(3) | | | | | | — | | | | | | 0.35 | | | | | | 12/1/2030 | | | ||
| | | 11,789,879(4) | | | | | | — | | | | | | 0.55 | | | | | | 9/2/2030 | | | ||
Leslie J. Goldman
Senior Vice President, General Counsel |
| | | | 24,500,000(5) | | | | | | — | | | | | | 0.23 | | | | | | 5/28/2028 | | |
| | | 20,000,000(6) | | | | | | — | | | | | | 0.35 | | | | | | 12/1/2030 | | | ||
| | | 8,554,455(6) | | | | | | — | | | | | | 0.35 | | | | | | 12/1/2030 | | | ||
| | | 5,894,939(7) | | | | | | — | | | | | | 0.55 | | | | | | 9/2/2030 | | | ||
Marnix L. Bosch
Chief Technical Officer |
| | | | 31,770(8) | | | | | | 21,355 | | | | | | 11.20 | | | | | | 6/23/2022 | | |
| | | 15,625(9) | | | | | | — | | | | | | 8.80 | | | | | | 8/20/2022 | | | ||
| | | 7,940,182(10) | | | | | | — | | | | | | 0.25 | | | | | | 6/13/2027 | | | ||
| | | 10,798,729(11) | | | | | | — | | | | | | 0.35 | | | | | | 7/2/2030 | | | ||
| | | 16,630,726(12) | | | | | | — | | | | | | 0.35 | | | | | | 12/1/2030 | | |
Name(3)
|
| |
Year
|
| |
Fees
Earned or Paid in Cash ($)(2) |
| |
Option
Awards ($)(1) |
| |
Total
($) |
| ||||||||||||
Dr. Navid Malik
|
| | | | 2021 | | | | | | 150,000 | | | | | | — | | | | | | 150,000 | | |
| | | 2020 | | | | | | 150,000 | | | | | | 4,123,000 | | | | | | 4,273,000 | | | ||
| | | 2019 | | | | | | 150,000 | | | | | | — | | | | | | 150,000 | | | ||
Jerry Jasinowski
|
| | | | 2021 | | | | | | 150,000 | | | | | | — | | | | | | 150,000 | | |
| | | 2020 | | | | | | 150,000 | | | | | | 1,497,000 | | | | | | 1,647,000 | | | ||
| | | 2019 | | | | | | 150,000 | | | | | | — | | | | | | 150,000 | | | ||
J. Cofer Black
|
| | | | 2021 | | | | | | 150,000 | | | | | | — | | | | | | 150,000 | | |
| | | 2020 | | | | | | 150,000 | | | | | | 1,250,000 | | | | | | 1,400,000 | | | ||
| | | 2019 | | | | | | 150,000 | | | | | | — | | | | | | 150,000 | | |
1 Year Northwest Biotherapeutics (QB) Chart |
1 Month Northwest Biotherapeutics (QB) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions